Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-06-12

Clinical Trial Update: Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) [Phase 2]

View source ↗

Summary

Phase 2 trial update for nivolumab in relapsed or refractory follicular lymphoma completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-06-12